reports
Emergent BioSolutions Reports First Quarter 2024 Financial Results
Emergent BioSolutions Reports First Quarter 2024 Financial Results First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance rangeFirst Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 millionUpdates FY 2024 guidance GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2024. "We delivered a strong quarter with growth across all our key products,” said Joe Papa, President and CEO at Emergent. “We also took significant act...
Emergent BioSolutions Announces Strategic Operational Changes to Stabi...
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position Proactive changes aim to ensure long-term sustainability and growth, optimize operations, streamline processes, and allocate resources more efficientlyReorganization will align with evolving business goals, strategic priorities and new operational planOverall efforts expected to deliver annual cost savings of approximately $80 million GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced the next phase of its new operational plan that consolidates...
Emergent BioSolutions Releases New Survey Findings Underscoring the Ne...
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone Nearly 9 in 10 Americans surveyed agree opioid overdoses are a concern for teenagers and college students; parents in the survey want life-saving treatment to be easily accessible in case of an emergency GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the results of a new national public opinion survey showing that more than 90 percent of Americans surveyed recognize opioid overdoses are a press...
Emergent BioSolutions Announces Amendment to its Existing Credit Facil...
Emergent BioSolutions Announces Amendment to its Existing Credit Facility GAITHERSBURG, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that it has entered into a “Consent, Waiver and Seventh Amendment” to its existing credit facility. “In light of this amendment, Emergent now has an extended runway to execute on our go-forward business plan to stabilize our financial position,” stated Joe Papa, president and CEO of Emergent. “Our bank group continues to work with our management team in a constructive fashion, evidenced by this positive developmen...
Emergent BioSolutions to Release First Quarter 2024 Financial Results ...
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024 GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024. Conference Call InformationParticipants can access the conference call live via . To participate via telephone, please register in advanc...
Emergent BioSolutions Continues to Broaden Access, Awareness and Avail...
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with NARCAN® Nasal Spray and build on its longstanding efforts with public interest entities across the country Hundreds of thousands of NARCAN® Nasal Spray cartons are available in over 32,000 retail locations in the U.S., and Emergent is working to increase reach into workplaces, businesses and oth...
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufa...
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or NAI status classification for the company's Baltimore Bayview manufacturing facility. Based on this outcome, the Baltimore Bayview facility is considered to be in an acceptable state of compliance with regard to current good manufacturing practices (cGMP). “Quality and compliance excellence remains a top priority for ...
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results Fourth Quarter 2023 Total Revenues of $277 million, which aligned our Full Year to the mid-point of guidanceFull Year 2023 Total Revenues of $1.05 billion, which was the mid-point of guidanceFourth Quarter 2023 Net Loss of $50 million and Adjusted EBITDA of $3 millionIssues Q1 2024 and FY 2024 guidance GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2023. "Emergent has a long history of helping p...
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Finan...
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024 GAITHERSBURG, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2023. Emergent’s newly appointed president and CEO, Joseph C. Papa, will provide remarks. Conference Call InformationParticipants can access the conference call live via webcast from the page of Emergent’s website. To par...
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New P...
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company’s debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller,...
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8...
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense GAITHERSBURG, Md., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract with a maximum value up to $235.8 million to supply BioThrax® (Anthrax Vaccine Adsorbed) for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease. The new contract with the U.S. Department of D...
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Health...
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024 GAITHERSBURG, Md., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a global company providing solutions that address public health threats and brings lifesaving, life-extending products to market, today announced that Haywood Miller, Interim Chief Executive Officer and Rich Lindahl, Chief Financial Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PT. The audio link for Emergent's session may be...
Emergent BioSolutions Receives $75 Million Contract Option from BARDA ...
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted) GAITHERSBURG, Md., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services has awarded a $75 million option to Emergent’s existing contract (HHSO100201600030C) for the acquisition of newly licensed anthrax vaccine CYFENDUS™ ...
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q...
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing GAITHERSBURG, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today confirmed that on November 16, 2023, the New York Stock Exchange (NYSE) sent a notice that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual due to a delay in filing its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 with the Securities and Exchange Commission (SEC). Notices are routinely issued by the NYSE in such situations. Under the NYSE’s rules, Eme...
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
Emergent BioSolutions Reports Third Quarter 2023 Financial Results Third Quarter 2023 Total Revenues of $271M, above the prior guidance rangeThird Quarter 2023 Pre-Tax Loss of $(266)M and Adjusted EBITDA(2) of $20MUpdates FY 2023 guidance GAITHERSBURG, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported selected financial results for the third quarter ended September 30, 2023. The selected financial results reported include limited third quarter and year-to-date results, as well as selected balance sheet and cash flow information. As part of ou...
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial ...
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023 GAITHERSBURG, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) has rescheduled its conference call to Wednesday, November 8, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2023, recent business developments, and financial outlook for full year 2023. The call will no longer take place on November 2, 2023. Conference Call InformationParticipants can access the conference call live via webcast from the...
Emergent BioSolutions to Release Third Quarter 2023 Financial Results ...
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023 GAITHERSBURG, Md., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 2, 2023, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2023, recent business developments, and financial outlook for full year 2023. Conference Call InformationParticipants can access the conference call live via webcast from the page of Emergent’s website. To participate via telephone, please re...
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Bo...
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent’s 2024 Annual Meeting of Stockholders. Both joined as independent directors and bring more than 70 years of combined biopharmaceutical industry and sales experience. “Neal and Don bring unique and extensive expertise to Emergent as the company defines its fu...
Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter M...
Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency Emergent has officially shipped its over the counter, original prescription strength NARCAN® Naloxone HCl Nasal Spray 4 mg to leading mass, drug/pharmacy and grocery stores, as well as online retailersNARCAN® Nasal Spray will be the first, life-saving emergency medicine for opioid overdose available on shelves beginning this September with a Manufacturer’s Suggested Retail Price of $44.99Emergent remains committed to ensuring broad access...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.